HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Model scores of the 29,894 trials active now.

Model score 33% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellscancertumortherapyrecurrent
  Phrases that lowered it: bodygroupbloodreceivelong
• Sponsor's past termination rate: 16.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 28.8% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 57 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 189 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 11146 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 53876 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers NCT01585428 · started 2012 · scored riskier than 99% of active trials completed
• HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer NCT03578406 · started 2018 · scored riskier than 48% of active trials completed
• T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers NCT02280811 · started 2014 · scored riskier than 99% of active trials completed
• E7 TCR T Cells for Human Papillomavirus-Associated Cancers NCT02858310 · started 2017 · scored riskier than 99% of active trials completed
• Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions NCT03937791 · started 2019 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.